UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19 - Seite 2

UNION is conducting the first human study at the Zelo Phase I Unit at Bispebjerg and Frederiksberg Hopsital as well as Center for Physical Activity Research at Rigshospitalet, in collaboration with Trial Nation Denmark and the Technical University of Denmark, and with financial support from the Innovation Fund Denmark.          

About UNION:

UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases.

The company is working on a versatile new mode-of-action chemistry platform, including well-characterized compounds as well as new chemical entities. The leadership team of UNION has successfully developed multiple approved drugs. UNION is headquartered in Copenhagen (Denmark) and managed by an experienced team across Europe and the USA. UNION has received financial support from the European Investment Bank's InnovFin program under Horizon 2020. Visit the Company's website at https://uniontherapeutics.com  

About Niclosamide

Niclosamide is approved as an oral anthelmintic. UNION has been working with niclosamide and the related chemical class for over six years and is currently conducting a Phase 2b study with niclosamide in atopic dermatitis patients. The Company has built extensive knowledge and intellectual property rights around the compound class, formulations and various methods of delivery as well as broadening the pipeline to cover additional diseases within inflammatory and infectious diseases.

About Niclosamide in COVID-19

Recent studies undertaken by the Institut Pasteur Korea, an infectious disease-focused research institute, have identified niclosamide as one of the most potent inhibitors of SARS-Cov-2; the virus causing COVID-19 based on in vitro studies. Niclosamide has the potential to become a truly differentiated treatment of COVID-19, effectively blocking replication of SARS-CoV-2 by targeting host cells to disrupt the viral life cycle.

Contact:
Morten Boesen
Chief Financial Officer
Tel: [phone]
Email: [e-mail]   

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-receives-approval-from-danish-medicines-agency-to-initiate-clinical-study-with-niclosamide-for,c3145312

The following files are available for download:

https://mb.cision.com/Main/19591/3145312/1272412.pdf

Press release (PDF)